Wed, 9 December 2015
Does the Specific EGFR Mutation (Including "Rare" Mutations) Matter When Choosing an Oral EGFR Inhibitor?
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
Direct download: GRACEcast-412_WCLC_2015_Specific_EGFR_Rare_Mutations_Matter_Oral_EGFR_Inhibitor.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT